Deutsche Bank just gave Idenix (NASDAQ: IDIX) a big buy recommendation, projecting a stock price of $7 per share, which is more than 55% higher than what the stock closed at yesterday, and the stock climbed 15% as a result. Its drug IDX-184 is still in development and on clinical hold because of its similarities with a drug from Bristol-Myers Squibb (NYSE: BMY) that had catastrophic results. But it's aimed at the hottest area in health care right now -- the treatment of hepatitis-C -- and Deutsche Bank thinks it is significantly different from Bristol's drug. Many wonder, however, if it isn't too late for a small company to enter this space, as drug cocktails demonstrating miraculous cure rates are already further along in development from both Abbott Labs (NYSE: ABT) and Gilead (NASDAQ: GILD).

See more in the following video.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.